Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Machine Learning to Predict Outcomes of Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration.

Ophthalmology science·2026

Same author

RetiMap: Automated Retinal Vascular Measures Link Microvascular Structure to Metabolic Health and Predict Cardiovascular Risk.

JACC. Basic to translational science·2026

Same author

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON.

Ophthalmology and therapy·2026

Same author

Artificial intelligence and medical retina training: A scoping review of educational opportunities, emerging risks, and curricular responses.

Survey of ophthalmology·2026

Same author

Insights into age-related macular degeneration.

Handbook of clinical neurology·2026

Same author

A large comprehensive comparison of large language models on ophthalmology board exams.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Search research articles

Related Experiment Video

Updated: Nov 26, 2025

Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases

Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases

Published on: October 6, 2023

Biosimilars for Retinal Diseases: An Update.

Ashish Sharma¹, Nilesh Kumar¹, Nikulaa Parachuri¹

¹Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India.

American Journal of Ophthalmology

|December 14, 2020

Summary

This summary is machine-generated.

The only approved ophthalmic biosimilar is Razumab, but many more anti-vascular endothelial growth factor biosimilars are in development for retinal diseases. These could lower treatment costs.

More Related Videos

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Published on: August 5, 2021

Author Spotlight: Advancements in In Vivo and Ex Vivo Retinal Imaging for Improved Glaucoma Diagnosis and Treatment

Author Spotlight: Advancements in In Vivo and Ex Vivo Retinal Imaging for Improved Glaucoma Diagnosis and Treatment

Published on: June 30, 2023

Related Experiment Videos

Last Updated: Nov 26, 2025

Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases

Author Spotlight: Advancing Vision Restoration - Stem Cell-Based Therapy for Retinal Diseases

Published on: October 6, 2023

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Subretinal Transplantation of Human Embryonic Stem Cell-Derived Retinal Tissue in a Feline Large Animal Model

Published on: August 5, 2021

Author Spotlight: Advancements in In Vivo and Ex Vivo Retinal Imaging for Improved Glaucoma Diagnosis and Treatment

Author Spotlight: Advancements in In Vivo and Ex Vivo Retinal Imaging for Improved Glaucoma Diagnosis and Treatment

Published on: June 30, 2023

Area of Science:

Ophthalmology
Pharmacology

Background:

Retinal diseases are often treated with expensive biologic therapies.
Anti-vascular endothelial growth factor (anti-VEGF) agents are crucial for managing various retinal pathologies.

Purpose of the Study:

To review the current status and development of biosimilars for anti-VEGF agents used in ophthalmology.
To provide an update on the pipeline of ophthalmic biosimilars.

Main Methods:

A comprehensive literature review was conducted.
Scientific articles, clinical trials, and press releases were analyzed.

Main Results:

Razumab is currently the only approved ophthalmic biosimilar.
Multiple biosimilar candidates targeting anti-VEGF pathways are in Phase 3 trials with promising results.

Conclusions:

Ophthalmic biosimilars have the potential to reduce the economic burden of biologic treatments for retinal diseases.
The widespread adoption and success of biosimilars may be influenced by the use of off-label bevacizumab in different regions.